Predictive Oncology’s (POAI) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Predictive Oncology (NASDAQ:POAI) in a research report sent to investors on Friday morning, Marketbeat.com reports. HC Wainwright also issued estimates for Predictive Oncology’s Q4 2025 earnings at $0.06 EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Stock Down 7.2 %

POAI stock opened at $0.69 on Friday. The stock has a market capitalization of $4.58 million, a P/E ratio of -0.23 and a beta of 1.14. The firm has a 50-day simple moving average of $0.75 and a 200-day simple moving average of $1.06. Predictive Oncology has a 52 week low of $0.55 and a 52 week high of $3.76.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.